A Pilot Evaluation of Ponatinib (AP24534), a Potent Oral Pan-FGFR Inhibitor, in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma: a Multi-Institutional Study

Trial Profile

A Pilot Evaluation of Ponatinib (AP24534), a Potent Oral Pan-FGFR Inhibitor, in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma: a Multi-Institutional Study

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2015

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Dec 2015 Status changed from not yet recruiting to withdrawn prior to enrolment according to ClinicalTrials.gov record.
    • 18 Sep 2015 Planned End Date changed from 1 Feb 2021 to 1 Jul 2023, as reported by ClinicalTrials.gov.
    • 18 Sep 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Jul 2018,as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top